PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are to be sold by PhaseBio. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Cowen, Stifel and William Blair are acting as joint book-running managers for the offering. Needham & Company is acting as lead manager for the offering.

You May Also Be Interested In

• Alkami Technology (ALKT) IPO Opens 37% Higher
• Optinose to Present at the Needham Virtual Healthcare Conference
• Nurix (NRIX) PT Raised to $48 at Needham & Company